IDH2 and neoplasm: Although pharmacological targeting of mutant IDH1 or IDH2 induces tumor cell differentiation through reduction of (R)2-HG production [15, 16], the inhibitory effect on glioma growth remains less clear [16, 17], and there are no appreciable changes in genome-wide DNA methylation [16].